Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics' stock has been impacted by several events in the past six months. The Q3 2025 earnings report showed an EPS of -$0.40, surpassing analysts' estimates. Guggenheim doubled its price target for TENX and named it a "Top Pick." The company participated in the Guggenheim Emerging Outlook Biotech Summit 2026. As of February 5, 2026, the stock price was $12.36, with a 52-week high of $18.38 and a low of $4.63. Insiders bought $149,053.00 in company stock and sold $0.00 in the three months leading up to February 8, 2026.

There is no indication of significant demand seasonality for Tenax Therapeutics' products or services. Demand for such medical treatments is typically driven by ongoing patient needs and disease prevalence rather than seasonal fluctuations.

Tenax Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for cardiovascular and pulmonary diseases with high unmet medical needs. Their primary focus is levosimendan, being evaluated for pulmonary hypertension associated with heart failure with preserved ejection fraction. The company relies on financing activities to fund its operations and clinical trials.

Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, and partners with pharmaceutical companies to market its products globally. Levosimendan has market authorization in 60 countries, excluding the United States and Canada, for its intravenous formulation.

Tenax Therapeutics has generally maintained a positive outlook from analysts in the past year. The consensus rating from Wall Street analysts is a "Moderate Buy" or "Buy," with an average 12-month price target ranging from $18.00 to $22.90. Successful private placements, advancement of clinical trials, a positive earnings beat, and analyst endorsements have positively affected its reputation.

Tenax Therapeutics has 44 institutional owners and shareholders holding a total of 4,817,692 shares. Major institutional owners include Ikarian Capital, LLC, VR Adviser, LLC, RTW Investments, LP, Siren, L.L.C., Boothbay Fund Management, LLC, Bvf Inc/il, Millennium Management LLC, Vanguard Group Inc, Vivo Capital, LLC, Morgan Stanley, Janus Henderson Investors US LLC, Venrock Associates and Invus Financial Advisors LLC. Approximately 1.67% of the stock is held by institutions, and 3.14% is held by insiders.